Amedisys Inc Stock Price, News & Analysis

Amedisys, Inc. has announced the appointment of Richard Ashworth as the new President and CEO, effective April 10, 2023, taking over from Paul Kusserow, who remains Chairman of the Board. Ashworth brings extensive operational and business development experience, having previously served as President and CEO of Tivity Health, achieving over 300% shareholder return. He also led Walgreens, managing $115 billion in revenue with a focus on digital transformation and employee engagement. His leadership is expected to drive excellence in home care services and foster innovation at Amedisys, which serves over 465,000 patients annually.

Amedisys (NASDAQ: AMED) partnered with nVoq to showcase findings from a 2022 study on speech recognition's impact on documentation quality at the PALTC23 conference in Tampa, Florida. The study revealed significant improvements in clinical narratives, including a 39% increase in prognostic statements and a 35% enhancement in disease progression documentation. Amedisys aims to improve operational efficiency and alleviate the documentation burden on healthcare professionals. This collaboration highlights the positive implications for patient care and clinician job satisfaction, as noted by Dr. Abi Katz and Chad Hiner during their presentation.

Amedisys, Inc. (NASDAQ: AMED), a premier home health and hospice service provider, announced key presentations by its CEO Paul Kusserow and Acting COO Scott Ginn. They will speak at Oppenheimer’s 33rd Annual Healthcare Conference on March 14 at 10:00 a.m. ET and at the Barclays Global Healthcare Conference on March 15 at 8:50 a.m. ET. Investors can access the live webcast via the company’s investor website. Amedisys offers personalized care services to over 465,000 patients annually through its 532 centers across 37 states. The company has relationships with over 102,000 physicians and more than 3,000 hospitals nationwide.

Amedisys has announced a strategic move to divest its Personal Care division to HouseWorks, enhancing its care coordination network. This partnership aims to provide seamless personal care services in several states, leveraging HouseWorks' footprint and eCaring's comprehensive software solutions. The CEO of Amedisys stated that this divestiture allows the company to focus on its core services in Home Health, Hospice, and High Acuity Care. The deal is expected to close in Q2 2023, demonstrating Amedisys' commitment to improving patient care delivery while maintaining a robust personal care network.

Amedisys, a provider of home health and hospice care, has announced a new agreement with BlueCross BlueShield of Tennessee to deliver palliative care at home for members in Middle Tennessee. This program focuses on patients with chronic or advanced illnesses, allowing them to receive in-person or telehealth care without additional costs. The initiative aligns with Amedisys' strategy to develop risk-based models with payers, enhancing patient quality of life while reducing hospitalizations. The company aims to expand its reach and improve care delivery in patients' homes.

Amedisys, Inc. (NASDAQ: AMED) reported its financial results for Q4 and the fiscal year ended December 31, 2022. Net service revenue increased by $2.7 million to $562.0 million year-over-year, while net income declined to $31.7 million from $34.0 million in 2021. For the full year, total revenue rose by $9.1 million to $2,223.2 million, but net income significantly dropped to $118.6 million from $209.1 million in 2021. The company provided 2023 guidance for adjusted net service revenue between $2.244 billion and $2.274 billion and adjusted EBITDA of $230 million to $240 million. Additionally, a divestiture of the personal care line was announced.

Amedisys, Inc. (NASDAQ: AMED) announced a stock repurchase program authorized by its Board of Directors, allowing the company to buy back up to $100 million of its common stock by December 31, 2023. Acting COO and CFO Scott Ginn emphasized the company's solid cash flow and low leverage as reasons for this strategic move, which will complement ongoing efforts in accretive acquisitions in Home Health and Hospice sectors. The repurchases will vary based on market conditions and can be executed through several methods, including open market purchases and private negotiations.

Amedisys, a leader in home health and hospice services, will announce its financial results for the fourth quarter and full year ending December 31, 2022, on February 15, 2023. The investor conference call is scheduled for February 16, 2023, at 11:00 a.m. ET. Callers can join via toll-free (877) 524-8416 or (412) 902-1028. A replay will be available until March 16, 2023. Amedisys provides personalized care through a network of over 532 care centers, catering to more than 465,000 patients annually. Founded in 1982, the company employs roughly 20,000 staff nationwide.